 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2...

Innate Pharma to Host Virtual KOL Event on Lacutamab

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2023. With our strong cash position, we...

Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to...

Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that several abstracts, including one oral presentation, have been selected for the 65th ASH (American...

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences...

Innate Pharma Announces Its Participation to Upcoming Investor Conferences

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today released its 2024 financial calendar: March 21, 2024: Publication of 2023 financial statements May 14, 2024...

Innate Pharma 2024 Financial Calendar

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO...

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023

Exchange Traded Concepts LLC purchased a new stake in Innate Pharma S.A. (NASDAQ:IPHA  Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the...

Exchange Traded Concepts LLC Purchases Shares of 42,431 Innate Pharma S.A. (NASDAQ:IPHA)

Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate...

Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND...

Innate Pharma Provides Update on Lacutamab Clinical Program

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Watchers	1,447
52-Wk Low	$1.81
52-Wk High	$3.97

Market Cap	$184.27M
Volume (M)	3,471.00
52-Wk High	$3.97
52-Wk Low	$1.81

IPHA Innate Pharma

About

Feed

News

Sentiment

Earnings

Fundamentals